Stock Research for EDT

Current Price


Latest Update: 2018-02-16 15:55:00

$ 0.3950
$ 0.3950
$ 0.3950

Featured Broker: TradeStation

Get the due diligence for another stock.


EDT Stock Chart & Research Data

The EDT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the EDT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


EDT Due diligence Resources & Stock Charts

The EDT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View EDT Detailed Price Forecast - CNN Money CNN View EDT Detailed Summary - Google Finance
Yahoo View EDT Detailed Summary - Yahoo! Finance Zacks View EDT Stock Research & Analysis -

Stock Analysis

TradeIdeas View EDT Trends & Analysis - Trade-Ideas Barrons View EDT Major Holders - Barrons
NASDAQ View EDT Call Transcripts - NASDAQ Seeking View EDT Breaking News & Analysis - Seeking Alpha
Spotlight View EDT Annual Report - OTC Report View EDT OTC Short Report -
TradeKing View EDT Fundamentals - TradeKing Charts View EDT SEC Filings - Bar Chart
WSJ View Historical Prices for EDT - The WSJ Morningstar View Performance/Total Return for EDT - Morningstar
MarketWatch View the Analyst Estimates for EDT - MarketWatch CNBC View the Earnings History for EDT - CNBC
StockMarketWatch View the EDT Earnings - StockMarketWatch MacroAxis View EDT Buy or Sell Recommendations - MacroAxis
Bullish View the EDT Bullish Patterns - American Bulls Short Pains View EDT Short Pain Metrics -

Social Media Mentions

StockTwits View EDT Stock Mentions - StockTwits PennyStocks View EDT Stock Mentions - PennyStockTweets
Twitter View EDT Stock Mentions - Twitter Invest Hub View EDT Investment Forum News - Investor Hub
Yahoo View EDT Stock Mentions - Yahoo! Message Board Seeking Alpha View EDT Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for EDT - Insider Cow View Insider Transactions for EDT - Insider Cow
CNBC View EDT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for EDT - OTC Markets
Yahoo View Insider Transactions for EDT - Yahoo! Finance NASDAQ View Institutional Holdings for EDT - NASDAQ

Stock Charts

FinViz View EDT Stock Insight & Charts - StockCharts View EDT Investment Charts -
BarChart View EDT Stock Overview & Charts - BarChart Trading View View EDT User Generated Charts - Trading View

Latest Financial News for EDT

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Posted on Wednesday December 31, 1969

Why CytoSorbents And Spectral Medical Inc Are Not Good Stocks For A Long Position
Seeking Alpha - Aug 4, 2017
CytoSorbents and Spectral Medical Inc. are two medical device companies that have much in common. One is based in US and the other in Canada.

Spectral Medical Inc. Completes $10 Million Bought Deal Financing
Marketwired (press release) - Feb 18, 2016
Spectral Medical Inc. ("Spectral" or the "Company"), (TSX:EDT)(OTCQX:EDTXF) announced that it has closed its previously announced bought deal financing pursuant to which it sold 14,300,000 common shares (the "Shares") of the Company to a syndicate of ...

The Reasons Why Spectral Medical's Sepsis Treatment Will Not Receive An FDA ...
Seeking Alpha - Jul 23, 2017
Recently Spectral Medical, Inc. (OTCPK:EDTXF), a small Canadian company, released trial results for its sepsis treatment (EAA and PMX).

Spectral Medical's sepsis treatment fails late-stage study
Reuters - Oct 3, 2016
(Reuters) - Spectral Medical Inc said its experimental treatment for sepsis - a common, oft-deadly complication of infection - failed a late-stage study, stymieing the company's plans to bring to market the first FDA-approved device for the condition ...
Toraymyxin Hemoperfusion Device Fails Sepsis Study - Managed Care magazine

Enter a stock symbol to view the stock details.